

1 **The β -NGF/TrkA signalling pathway is associated with the production of**
2 **anti- nucleoprotein IgG in convalescent COVID-19**

3 **Carla Usai¹, Joseph M. Gibbons^{1†}, Corinna Pade^{1†}, Wenhao Li^{1,2}, Sabina R.M. Jacobs¹, Áine**
4 **McKnight¹, Patrick T. F. Kennedy^{1,2*} & Upkar S. Gill^{1,2*}**

5 ***Joint senior & corresponding authors**

6 **†These authors have contributed equally to this work**

7 ¹Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and
8 Dentistry, Queen Mary University of London, London, United Kingdom.

9 ²Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom.

10 *** Correspondence:**

11 Dr Upkar S. Gill & Professor Patrick T.F. Kennedy
12 u.gill@qmul.ac.uk; p.kennedy@qmul.ac.uk

13 **Keywords: COVID-19, antibody production, β -NGF, T cells, SARS-CoV-2.**

14 **Abstract**

15 **Background.** The presentation of SARS-CoV-2 infection varies from asymptomatic to severe
16 COVID. Similarly, high variability in the presence, titre and duration of specific antibodies has been
17 reported. While some host factors determining these differences, such as age and ethnicity have
18 been identified, the underlying molecular mechanisms underpinning these differences remain poorly
19 defined.

20 **Methods.** We analysed serum and PBMC from 17 subjects with a previous PCR confirmed SARS-
21 CoV-2 infection and 10 unexposed volunteers following the first wave of the pandemic, in the UK.
22 Anti-NP IgG and neutralising antibodies were measured, as well as a panel of infection and
23 inflammation related cytokines. The virus-specific T cell response was determined by IFN- γ
24 ELISPOT and flow cytometry after over-night incubation of PBMCs with pools of selected SARS-
25 CoV-2 specific peptides.

26 **Results.** Seven of 17 convalescent subjects had undetectable levels of anti-NP IgG, and a positive
27 correlation was shown between anti-NP IgG levels and the titre of neutralising antibodies (IC50). In
28 contrast, a discrepancy was noted between antibody levels and T cell IFN- γ production by ELISpot
29 following stimulation with specific peptides. Among the analysed cytokines, β -NGF and IL-1 α levels
30 were significantly different between anti-NP positive and negative subjects, and only β -NGF
31 significantly correlated with anti-NP positivity. Interestingly, CD4+ T cells of anti-NP negative
32 subjects expressed lower amounts of the β -NGF-specific receptor TrkA.

33 **Conclusions.** Our results suggest that the β -NGF/TrkA signalling pathway is associated with the
34 production of anti-NP specific antibody in mild SARS-CoV-2 infection and the mechanistic regulation
35 of this pathway in COVID-19 requires further investigation.

36 **Introduction**

37 SARS-CoV-2 infected subjects can display symptoms within a wide range of severity, from
38 asymptomatic or pauci-symptomatic forms (characterised by fever, cough, fatigue, sore throat, loss
39 of smell) to respiratory failure and systemic manifestations (sepsis, septic shock, and multiple organ
40 dysfunction syndromes (1). Similarly, high variability in the presence, titre and duration of specific
41 antibodies has been reported (2–4), often positively correlating with disease severity (3–5).

42 Some factors determining differences in clinical manifestations and humoral response, such as age,
43 ethnicity and co- or pre-existing medical conditions have already been described (2,6). Underlying
44 genetic and molecular determinants of humoral responses are currently being investigated with
45 some promising results, although these studies mainly focussed on subjects experiencing severe
46 COVID-19 (7–9).

47 It is estimated that 90-99% of PCR confirmed SARS-CoV-2 infected individuals mount a specific
48 humoral response, while 1-10% have very low to undetectable anti-spike (S) or anti-nucleoprotein
49 (NP) IgG by commercial serological assays (4,10–12). Likewise, specific SARS-CoV-2 T cells have
50 been detected in the majority of COVID-19 convalescent patients, even in cases where humoral
51 responses are undetectable (13,14).

52 While the presence of IgG against S and NP of SARS-CoV-2 are known to be detected with varying
53 kinetics (3,15), T cell responses appear to be simultaneously directed to several antigens from early
54 phases of SARS-CoV-2 exposure (16,17). The possibility of an existing hierarchy with some of the
55 viral antigens being more efficient in eliciting a T cell response, or because of cross-reactive T cells
56 due to previous infections in some individuals has been considered (5,18,19).

57 It has been described that an early T cell response during active SARS-CoV-2 infection is
58 associated with milder symptoms and rapid viral clearance (5). Regarding the humoral response,
59 associations between anti-NP and anti-S dominated early responses with different outcomes have
60 been found in independent studies, with severe COVID-19 patients showing an early response
61 dominated by anti-NP antibodies, and mild to moderate cases exhibiting a dominant anti-S response
62 (5,20,21). A better characterisation of such inter-individual variability identifying prognostic factors

63 will allow better stratification according to the relative risk of developing severe disease, which may
64 be key to prioritise future treatment and vaccination strategies.

65 To address this question, we utilised a cohort of subjects sampled immediately following the first
66 wave of the COVID-19 pandemic in the UK; we analysed serum samples and peripheral
67 mononuclear cells (PBMC) from 7 anti-NP negative, 10 anti-NP positive COVID-19 convalescent
68 subjects, and 10 unexposed volunteers. We determined the titres of neutralising antibodies, the
69 presence of antigen-specific T cells, and serum levels of cytokines related to infection and
70 inflammation, to identify host factors associated with anti-NP IgG positivity. We identify an
71 association between the presence of circulating anti-NP antibodies and the nerve growth factor (β -
72 NGF)/TrkA pathway, known to be active in lymphocytes and to be involved in inflammatory
73 conditions of the airways (22–25).

74 **Material and Methods**

75 **Convalescent COVID-19 and Healthy Donors**

76 Forty donors were randomly selected from a previously published cohort (2) to create four sex- and
77 age-matched groups according to PCR and antibody status. Group 1: negative PCR and negative
78 anti-NP IgG n=10 (“unexposed”); Group 2: positive PCR and positive anti-NP IgG n=10; Group 3:
79 positive PCR and negative anti-NP IgG n=7; negative or n/a PCR and positive anti-NP IgG n=13. All
80 participants provided informed consent according to the local ethics committee approval (Approved
81 22/04/2020, South Central - Berkshire Research Ethics Committee ref: 20/SC/0191,
82 ISRCTN60400862).

83 **Sample Collection**

84 Venepuncture was performed on each participant utilising the sites standard blood collection
85 method. 40 ml of whole blood were collected in EDTA plasma vacutainers for serum collection and
86 lithium heparin tubes for peripheral blood cell isolation. Serum samples were obtained by
87 centrifugation of 5 ml venous blood at room temperature at 3,000 g for 15min, aliquoted and frozen
88 on the day of collection.

89 **PBMC isolation**

90 PBMCs were isolated from heparinised blood by density gradient centrifugation on Ficoll-Paque
91 (2000 rpm for 23 minutes at room temperature with minimum deceleration speed) and cells

92 immediately frozen in fetal bovine serum 10% DMSO. Cells were thawed on the day of
93 experimentation and used directly for the *ex vivo* experiments.

94 **Antibody tests**

95 The presence of anti-Nucleocapsid protein (NP) IgG and IgM in serum samples was determined
96 using the Panbio™ COVID-19 IgG/IgM Rapid Test Device (Fingerstick Whole Blood/Venous Whole
97 Blood/Serum/Plasma) (Panbio™; Abbott Rapid Diagnostics Jena GmbH, Jena, Germany) according
98 to the manufacturer's instructions and as previously described (2). Anti-NPIgG levels in serum
99 samples were quantified using the Abbott Architect i2000 chemiluminescent microparticle
100 immunoassay (Architect) was for SARS-CoV-2 IgG (Abbott Diagnostics, IL, USA; Architect)
101 according to the manufacturer's instructions and as previously described (2).

102 **Authentic Virus Neutralisation Assay**

103 SARS-CoV-2 microneutralisation assay was performed as described previously (14,26). VeroE6
104 cells were seeded in 96-well plates 24h prior to infection. Duplicate titrations of heat-inactivated
105 patient sera were incubated with 3x10⁴ FFU SARS-CoV-2 virus (TCID₁₀₀) at 37°C for 1h.
106 Serum/virus preparations were added to cells and incubated for 72h. Surviving cells were fixed in
107 3.7% (vol/vol) formaldehyde and stained with 0.1% (wt/vol) crystal violet solution. Crystal violet stain
108 was resolubilised in 1% (wt/vol) sodium dodecyl sulphate solution. Absorbance readings were taken
109 at 570nm using a CLARIOStar Plate Reader (BMG Labtech). Negative controls of pooled pre-
110 pandemic sera (collected prior to 2019), and pooled serum from neutralisation positive SARS-CoV-2
111 convalescent individuals were spaced across the plates. Absorbance for each well was standardised
112 against technical positive (virus control) and negative (cells only) controls on each plate to determine
113 percentage neutralisation values. IC₅₀s were determined from neutralisation curves. All authentic
114 SARS-CoV-2 propagation and microneutralisation assays were performed in a containment level 3
115 facility.

116 **Cytokine analysis**

117 Serum levels of a customised panel of cytokines and chemokines were determined using cytokine
118 bead assay (CBA) kits (Bio-Techne Ltd) on a Magpix (Luminex Corporation) equipped with
119 xPonent® software for data acquisition and analysis. According to the manufacturers instruction,
120 serum samples were diluted at a ratio of 1:2 for the determination of Leptin, CCL2, GM-CSF, HGF,
121 IFN- γ , IL-1 α , IL-1 β , IL-6, IL-8, IL-10, IL-12 p70, β -NGF, PBEF/Visfatin, Resistin, PAI 1, TNF- α and
122 VEGF concentration; 1:200 for Adiponectin, Serpin A12 and C reactive protein, and 1:400 for RBP4
123 analysis.

124

125 **SARS-CoV-2 peptide pools**

126 Twenty peptides from the Spike, Membrane, Nucleoprotein and ORF-7a-2 proteins of SARS-CoV-2
127 containing T cell epitopes with known immunogenic properties (17,27) were purchased from
128 Prolimmune Limited. The purity of the peptides was above 80%, and their composition was
129 confirmed by mass spectrometry analysis. Single peptides were reconstituted in DMSO and pooled
130 as outlined in **Table 1** and used at a final concentration of 2 μ M, reconstituted in RPMI.

131 **IFN- γ ELISPOT assay**

132 IFN- γ ELISpot assays were performed with cryopreserved PBMCs, using human IFN- γ ELISPOT
133 Set (BD, 551849). PBMC were thawed, washed twice in RPMI media, and seeded at a final
134 concentration of 2×10^5 cells/100 μ l and stimulated for 18 hours with 100 μ l/well of each peptide pool
135 at a final concentration of 1 μ M/peptide/well, at 37°C, 5% CO₂. Treatment with PMA (Abcam,
136 ab120297) and Ionomycin (Abcam ab120370) (final concentration 250 ng/ 5 μ g/ ml respectively)
137 was used as a positive control, while RPMI was added to unstimulated cells. Spot forming units
138 (SFU) were quantified with a BIOREADER® 7000–F (BioSys GmbH). To quantify positive peptide-
139 specific responses, 2x mean spots of the unstimulated wells were subtracted from the peptide-
140 stimulated wells, and the results expressed as SFU/10⁶ cells.

141 **T cell expansion**

142 Frozen PBMCs were thawed and washed twice in 5 ml RPMI medium, centrifuged at 1500 rpm for 5
143 min and resuspended at a final concentration of 2×10^6 /ml in RPMI 10%FBS 2 μ M Monensin
144 (eBioscience, 00-4505-51). 100 μ l cell suspensions were stimulated in a 96-well plate for 18 hours
145 with 100 μ l/well of each peptide pool, at a final concentration of 1 μ M/peptide/well, at 37°C, 5% CO₂.
146 Treatment with PMA (Abcam, ab120297) and Ionomycin (Abcam ab120370) at the final
147 concentration of 50 ng/ml and 1 μ g/ml respectively, was used as a positive control, while RPMI was
148 added to unstimulated cells. Cells were washed in 100 μ l PBS 1x. Each well was incubated for 20
149 min at 4°C in the dark, with saturating concentrations (100 μ l) of a mix of the following antibodies:
150 anti-PD1 PE-Cy7 (BioLegend, clone EH12.2H7), anti-CD8 APC-Cy7 (BioLegend, clone SK1), anti-
151 TrkA PE (R&D Systems), anti-CD3 V500 (BD Biosciences, clone UCHT1), anti-CD4 BV605
152 (BioLegend, clone OKT4), anti-CD69 AF700 (BioLegend, clone FN50), anti-KLRG1 PerCP
153 (BioLegend). The Blue Fluorescent Reactive Dye (Invitrogen, L23105) was added to the mix to
154 assess cell viability. Cells were subsequently fixed and permeabilized using the Cytofix/Cytoperm kit
155 (BD Biosciences — Pharmingen) (100 μ l/well for 30 min at 4°C in the dark) and stained with anti-

156 IFN- γ BV450 (BD Biosciences, clone B27), anti-TNF- α APC (BioLegend, clone Mab11), anti-IL-2
157 PE-CF594 (clone 5344.111, BD Horizon), anti-MIP-1 β FITC (clone D21-12351 BD Pharmingen).
158 Cells were acquired on a BD-LSR II FACS Scan, and data were analysed using FlowJo (Tree Star
159 Inc.).

160 **Statistical analysis**

161 Statistical analysis was performed using GraphPad Prism 9.1.2, GraphPad Software, San Diego,
162 California USA, (www.graphpad.com). Specific statistical tests for each experiment are included in
163 the representative figure legends; p values <0.05 were considered significant. Binary logistic
164 regression was performed using IBM SPSS Statistics for Windows, Version 27. Armonk, NY: IBM
165 Corp.

166 **Results**

167 **Discordant antibody levels relative to T cell responses**

168 We have previously determined the anti-NP IgM and IgG levels of 228 volunteers, after the first
169 wave of the pandemic in the United Kingdom (2). Seven out of 87 participants who had had a
170 positive PCR test, had undetectable levels of anti-NP IgG, irrespective of symptomatology (**Table 2**).
171 Forty donors were randomly selected into four sex- and age-matched groups (**Supplementary**
172 **Table 1**), and their T cell response to selected peptide pools was analysed with IFN- γ ELISPOT (of
173 the 7 PCR positive, anti-NP IgG negative subject, only 4 had given their consent for additional
174 PBMC isolation).

175 A large proportion (80%) of subjects who were PCR negative, anti-NP IgG negative did not produce
176 IFN- γ following SARS-CoV-2 peptide stimulation, whereas 83% of those demonstrating PCR
177 positivity, regardless of anti-NP IgG status, demonstrated positive ELISPOT responses as marked
178 by IFN- γ spot-forming units (SFUs). In subjects where a PCR result was not available, 7 of 9 (78%)
179 demonstrated evidence of IFN- γ production after overnight stimulation with the selected peptide
180 pools, with a proportion of responders close to that of the PCR positive anti-NP positive group (7 out
181 of 8, 87.5%) (**Figure 1A**). Deconvoluting the total T cell responses into individual peptide pools,
182 derived from four SARS-CoV-2 proteins (Membrane – M, Nucleoprotein –NP, ORF-7a-2, and Spike
183 –S), we observed a similar number of responders with a similar distribution among the groups.
184 Surprisingly, however those PCR positive anti-NP IgG negative subjects did not produce recordable
185 IFN- γ responses following stimulation with the pool of peptides derived from S (**Figure 1B**). Since
186 we considered the PCR status as one of the defining characteristics of our subject cohorts, we
187 elected to exclude the subjects where PCR results were not available from subsequent analyses.

188 In addition to the Abbott Architect and Panbio assay for anti-NP IgG measurement, we determined
189 the presence and titre of neutralising antibodies (nAbs) which has the receptor binding domain
190 (RBD) of the S protein as their major target. In all subjects where anti-NP IgG positivity was
191 demonstrated, high nAb titres (IC₅₀>200) were noted. Neutralising antibody titres were absent
192 (IC₅₀<50), as expected, in all PCR negative subjects but also in two of seven PCR positive subjects
193 with negative anti-NP IgG status. In the five subjects where, anti-NP was negative but nAbs were
194 detectable, two displayed low titres (IC₅₀=50-199) and three high titres (**Figures 2A and 2B,**
195 **Supplementary Figure 1A and 1B**). While a positive correlation was found between the level of
196 anti-NP IgG and the titre of nAbs (**Supplementary Figure 1C**), there was discordance between
197 antibody levels (either anti-NP or nAbs) and the cumulative T cell response expressed in SFU per
198 million cells (**Figure 2C**), similar to that previously reported (14).

199 **Multi-specific and differential CD4 and CD8 T cell cytokine responses according to PCR** 200 **and antibody status**

201 We then wanted to determine the presence of antigen-specific T cell populations in the peripheral
202 blood of the donors. 2 x 10⁵ PBMCs were stimulated overnight with four peptide pools derived from
203 SARS-CoV-2 and analysed by flow cytometry for the production of IL-2, TNF- α , IFN- γ , and MIP-1 β
204 (**Supplementary Figure 2**).

205 The peptide stimulation following incubation induced the expansion of a small percentage of
206 antigen-specific CD4⁺ T cells (<1% on average for IL-2, TNF- α and MIP-1 β , and <5% for IFN- γ); the
207 frequency of IFN- γ producing S-specific cells was higher in PCR positive anti-NP negative subjects
208 compared to unexposed volunteers, and no other significant difference was detected between
209 groups (**Figure 3A**). Among the studied cytokines from CD4⁺ T cells, TNF- α was produced by the
210 highest proportion of individuals across all groups, ranging from 25% to 100% of subjects depending
211 on the group and the peptide pool used for stimulation, while IL-2 was produced by the lowest
212 proportion of subjects (11%-50%) (**Figure 3C**).

213 Cytokine production from antigen-specific CD8⁺ T cells was similarly low when examining IL-2, MIP-
214 1 β and IFN- γ (<1% on average for IL-2 and MIP-1 β , <5% for IFN- γ), but higher for TNF- α producing
215 cells (up to 4% on average). Moreover, only IL-2- producing S-specific CD8⁺ T cells were present at
216 a higher frequency in PCR positive anti-NP positive subjects than unexposed controls and no other
217 significant differences were detected (**Figure 3B**). MIP-1 β was the cytokine produced by the highest
218 proportion of individuals across groups, ranging from 0% to 100%, depending on the group and the
219 peptide pool used for stimulation, followed by IL-2 and IFN- γ (20% and 11% respectively, up to

220 75%), while TNF- α from CD8+ T cells was produced by lower proportions of subjects (0% to 50%)
221 (**Figure 3D**).

222 However, when considering the cumulative response of cytokine production to the peptide pools,
223 differences between groups were identified. Within the PCR positive anti-NP positive group the
224 strongest cumulative cytokine production from CD4+ T cells was noted in response to the pool
225 derived from the S protein, with 12.5% of the subjects producing all analysed cytokines; all cytokines
226 were produced with the same frequency in response to this pool. This was followed, in decreasing
227 order, by the pools derived from M (TNF- α and IFN- γ being the predominant cytokines), NP (which
228 induced MIP-1 β in 50% of cases), and ORF-7a-2 (mainly inducing TNF- α and MIP-1 β). On the
229 contrary, within the PCR positive anti-NP negative group, the greatest cytokine production was
230 achieved in response to the pool derived from the M protein (25% of subjects producing all
231 cytokines, and all producing TNF- α). This was followed by the pools derived from NP (mainly
232 inducing TNF- α) and ORF-7a-2 (inducing the production of TNF- α , IFN- γ and MIP-1 β with the same
233 frequencies). The peptide pool derived from S elicited the lowest cumulative cytokine production,
234 dominated by TNF- α and IFN- γ (**Figure 4A**).

235 A similar pattern was observed for CD8+ T cells from the PCR positive, anti-NP positive subjects,
236 with S inducing the strongest cumulative cytokine production (12.5% of subjects producing four
237 cytokines, all of them producing at least one cytokine, and MIP-1 β being expressed with the highest
238 frequency). For the remaining pools, 25-37.5% of subjects failed to produce any cytokine; the
239 response was dominated by MIP-1 β in the case of the pools derived from M and NP, and by MIP-1 β
240 and IL-2 in the case of the peptide derived from ORF-7a-2. However, CD8+ T cells from 25% of the
241 PCR positive anti-NP negative subjects were also able to produce four cytokines in response to the
242 S pool. The lowest cytokine response was elicited by the peptide pool derived from NP, which
243 induced the production of only one or two cytokines per subject sample (TNF- α was induced in three
244 out of four subjects). The pools derived from M and ORF-7a-2 were able to elicit the production of
245 up to three cytokines in two and three subjects out of four respectively, but while the response to M
246 was dominated by MIP-1 β , the cytokine induced at the highest frequency in response to ORF-7a-2
247 was IL-2 (**Figure 4B**). These results suggest that a differential hierarchy of response exists among
248 PCR positive subjects, according to their ability to produce anti-NP antibodies.

249 **Distinct serum cytokine profiles in relation to anti-NP status**

250 In order to understand whether the differences in the antibody production and T cell response
251 reflected different cytokine profiles, we analysed the levels of 20 infection and inflammation related
252 cytokines in the serum of the selected subjects (**Figure 5A**). GM-CSF, β -NGF, IL-1 α , PBEF/Visfatin

253 and IL-12 p70 were found to positively correlate with anti-NP IgG levels (**Figure 5A and 5D, Table**
254 **3**), and among them, β -NGF and IL-1 α levels were significantly different between PCR positive, anti-
255 NP positive and PCR positive, anti-NP negative subjects (**Figure 5B and 5C**). No correlation was
256 found between serum β -NGF levels and IC50 (**Figure 5E**). A binary logistic regression analysis
257 performed considering anti-NP positivity as a binary variable, confirmed that only β -NGF levels
258 directly correlate with the presence of anti-NP IgG (OR: 11.038, p value=0.010) (**Table 4**).

259 **T cells from anti-NP IgG negative subjects express lower levels of the β -NGF receptor**
260 **TrkA.**

261 Noting that circulating levels of the serum cytokine β -NGF positively associated with the production
262 of anti-NP IgG, we further investigated the implications of this pathway in this setting. β -NGF has
263 been shown to be important in other respiratory viruses, such as RSV (26,27). It is produced by T
264 cells and involved in an induction loop with its receptor Tropomyosin receptor kinase A (TrkA). In
265 line with this, we studied TrkA expression on CD4+ and CD8+ T cells by flow cytometry in relation to
266 β -NGF levels with the different cohorts.

267 Although the expression of TrkA on both CD4+ and CD8+ T cells appeared low, we were able to
268 demonstrate that by MFI of TrkA on CD4+ T cells positively correlated with serum levels of β -NGF in
269 the whole cohort (**Figure 6A**), yet this parallel was not seen for CD8+ T cells (Figure 6B). The
270 percentage of CD4+ and CD8+ T cells expressing the β -NGF related receptor TrkA was similar
271 between the groups (**Figure 6C and 6D**); however, CD4+ T cells from anti-NP IgG positive subjects
272 express higher levels of TrkA on their surface, when analysed by median fluorescence intensity
273 (MFI) (**Figure 6E**). The same discrepancy, however, was not identified for CD8+ T cells (**Figure 6F**),
274 suggesting a preferential involvement of CD4+ T cells in this β -NGF/TrkA signalling pathway,
275 implying the potential for CD4+ T cell help in this setting.

276 We then compared TrkA expression (by MFI) on antigen specific CD4+ TrkA+ and CD8+ TrkA+ T
277 cells, to establish if there were discrepancies in relation to SARS-CoV-2 peptide specificities and this
278 signalling pathway. We did not detect any differences in cytokine producing cells between groups
279 with regards to antigen specific CD4+ TrkA+ cells, disparate to the findings on global CD4+ T cells
280 (**Figure 6G**). Overall, cytokine production from CD8+ T cells (by MFI) remained very low, and
281 although differences were detected between both peptide specificities and groups, we would
282 interpret these findings with caution (**Figure 6H**).

283

284 **Discussion**

285 Despite the success of the vaccine against SARS-CoV-2 in preventing severe COVID-19, there
286 remains a substantial burden of COVID-19 on healthcare services globally. A deeper understanding
287 of the immune response to SARS-CoV-2 infection and of its inter-individual variability is of a great
288 importance for the implementation of further vaccination strategies during the second year of the
289 pandemic and in the forthcoming years. There has been great progress made in the understanding
290 of the host-virus interaction and the pathogenesis of SARS-CoV-2, mostly limited to severe cases.
291 However, as it was already suggested by early reports (28), SARS-CoV-2 infection leads to mild
292 disease in the majority of cases. An extensive characterisation of the functionality and durability of
293 the immune response in subjects with mild COVID-19 will be instrumental for an in depth risk
294 evaluation and more efficient utilisation of treatment and prophylaxis strategies.

295 In this work, we analysed the SARS-CoV-2 specific T cell response and the cytokine profile of 17
296 mild COVID-19 convalescent subjects (positive PCR test) and 10 unexposed subjects (negative
297 PCR test, no symptoms) from a previously published cohort (2), to determine host factors
298 influencing primarily the production of anti-NP antibodies, but also neutralising antibodies. Our initial
299 observation was that seven out of eighty (8.75%) PCR confirmed subjects in our cohort had
300 undetectable anti-NP IgG, in line with other published cohorts where 1-10% of subject did not
301 seroconvert (4,10–12).

302 We analysed the T cell response by IFN- γ ELISPOT assay. Interesting we noted differences
303 between anti-NP IgG positive and anti-NP IgG negative convalescent patients, where none of the
304 anti-NP negative subjects were able to produce IFN- γ after stimulation with peptides derived from
305 the S protein. Of note, two out of the four analysed anti-NP IgG negative subjects had a detectable
306 IFN- γ response after overnight incubation with peptides derived from NP. This is not surprising,
307 since a SARS-CoV-2 specific T cell response has been detected in mild COVID-19 convalescent
308 subjects even in the absence of seroconversion (29), and the T cell response rather than humoral
309 response is considered to have a determining role in viral clearance (30) as recently shown in rapid
310 abortive SARS-CoV-2 infection (31).

311 While anti-NP IgG are representative of the humoral response, since they are directed against a
312 very abundant viral protein found inside viral particles or infected cells, they are not indicative, per
313 se, of effective immunity, where the considered hallmark is neutralising antibodies. Thus, we
314 determined the titres of nAbs in our cohort, showing that the IC50 positively correlated with anti-NP
315 levels (Architect Index) in the overall cohort. However, five out of seven anti-NP negative subjects
316 showed evidence of neutralising activity, discordant with the Architect Index. A similar discrepancy
317 between antibody presence and T cell response was observed, where anti-NP IgG presence/titre
318 and or nAbs did not correlate with T cell responses. Similar incongruity has been shown in a larger

319 cohort of healthcare workers, where a multi-specific T cell response was not always associated to
320 the presence of nAbs (14).

321 To further characterise the T cell response in our cohort we analysed the production of four effector
322 cytokines. While the frequencies of antigen-specific T cells were not different between groups, we
323 observed that T cells from anti-NP positive and negative subjects reacted differently to the peptide
324 pools in terms of number of cytokines produced after overnight stimulation. Particularly, CD4+T cells
325 from anti-NP positive subjects reacted preferentially to peptides derived from S (12.5% of them
326 produced four cytokines after stimulation), followed by the pools derived from M, NP and ORF-7a-2.
327 On the contrary, CD4+ T cells from anti-NP negative subjects reacted weakly to the S-derived pool
328 in comparison to the other antigens and reacted preferentially to M-derived peptides followed by the
329 pools derived from NP and ORF-7a-2. CD8+ T cells from anti-NP IgG positive subjects also strongly
330 reacted to the S-derived pool; CD8+ T cells from anti-NP negative subjects responded similarly to
331 the S pool, while reacted weakly to NP-derived peptides. These observations suggest that a
332 differential hierarchy of cytokine response exists among convalescent subjects, in relation to their
333 ability to produce anti-NP antibodies.

334 The presence of specific antibodies in our cohort does not directly correlate with the detection of the
335 corresponding antigen specific CD4+ T cells. While none of the four anti-NP subjects for whom
336 PBMC were available produced IFN- γ against S in the ELISPOT assay, three produced at least one
337 cytokine against the same pool when analysed by flow cytometry, and all had detectable nAbs.
338 Similar findings were reported by Marklund et al., (4) where all subjects with mild COVID-19, with
339 undetectable anti-NP IgG demonstrated neutralising activity. However, in our case, a direct
340 correlation between these results cannot be deduced since the S-derived peptides used in our
341 experiments do not cover the RBD. In addition, we were unable to study the T cell response of the
342 two anti-NP negative subjects lacking nAbs, since their PBMC were not available.

343 To further ascertain if soluble circulating factors may govern anti-NP production, we analysed a
344 panel of cytokines related to infection and inflammation from the serum of subjects between groups.
345 Surprisingly, we found that anti-NP positive and anti-NP negative subjects differed in the levels of
346 only two serum cytokines, β -NGF and IL-1 α . A linear correlation was also found between Architect
347 Index values and serum levels of GM-CSF, β -NGF, IL-1 α , PBEF and IL-12 p70. However, since the
348 relationship between Architect Index and the subject's IgG concentration is monotonic but not
349 necessarily linear across its range, we decided to consider the presence of anti-NP IgG as a binary
350 variable (either positive or negative), and perform a binary logistic regression, from which only β -
351 NGF levels positively correlated with anti-NP IgG positivity. On the contrary, no correlation was

352 found between β -NGF serum levels and nAbs titres, suggesting that the production of anti-NP and
353 nAbs may be subject to different dynamics and kinetics.

354 β -NGF is the active form of the first discovered member of a family of neurotrophines (32,33). It is
355 expressed and released by a variety of cell types including T and B lymphocytes (22,23,34); its low
356 basal expression levels increase during inflammation, and it can be induced by pro-inflammatory
357 cytokines such as IL-1 β , TNF- α and IL-6 (35,36). The biological effects of β -NGF are mediated by
358 two receptors: p75NTR (low-affinity, can bind other neurotrophines) and Tropomyosin receptor
359 kinase A (TrkA, high affinity and β -NGF-specific) (25,35). Activation of the TrkA receptor leads to cell
360 survival, proliferation, differentiation, and activation. Engagement of the low affinity p75NTR receptor
361 in the absence of TrkA activates the pro-apoptotic pathway. Basal expression of TrkA is up-
362 regulated on B and T cells after antigenic or inflammatory stimulation; moreover, in some cell types,
363 expression or circulating levels of β -NGF strongly correlate with TrkA expression, suggestive of a
364 positive feedback loop (37,38). Since the high-affinity TrkA receptor is expressed on human CD4+ T
365 cells (24), we determined its expression by flow cytometry on T cells isolated from subjects in our
366 cohort. We observed that the frequency of CD4+ TrkA+ T cells was similar in all three groups, but
367 the median fluorescence intensity (MFI), indicative of the quantity of TrkA molecules expressed on
368 the surface of the cells, was lower in the anti-NP negative than in the anti-NP positive subjects. Such
369 difference, however, was not confirmed in antigen specific CD4+ T cells, where high variability within
370 groups was observed. β -NGF serum levels positively correlated with TrkA expression on global
371 CD4+ T cells, as expected based on the suggested positive feedback loop between the cytokine
372 and its receptor.

373 Due to the cross-sectional nature of our study, we are not able to determine whether the β -NGF
374 levels observed are either a consequence of the recent SARS-CoV-2 infection or reflect the basal
375 levels of our subjects. However, since β -NGF basal levels are normally low, it is possible that the
376 lower plasma levels observed in the anti-NP negative subjects reflect an attenuated inflammatory
377 response experienced by these subjects during the infection; this would be in line with the more
378 severe presentation of the disease in patients with an anti-NP dominated humoral response
379 (5,20,21).

380 Interestingly, β -NGF has been studied in the contexts of respiratory syncytial virus (RSV), and
381 human rhinovirus (HRV) infection, where it inhibits apoptosis of the bronchial epithelial cells
382 supporting viral replication, and promotes virus internalisation, respectively (39,40). To our
383 knowledge, an involvement of β -NGF in SARS-CoV-2 infection has not been investigated, but our
384 results indicate a potential association between the β -NGF/TrkA signalling pathway and the

385 production of anti-NP antibodies, which in turn reflects a different degree of inflammation caused by
386 SARS-CoV-2 infection.

387 We acknowledge the limitations of our study, in part linked to the difficulties in diagnosis during the
388 early phase of the pandemic, when PCR testing was not widely available. For this reason, we were
389 not able to determine the exact timeframe between symptom onset, PCR test and sample collection
390 for most of our subjects. Moreover, our sample size was limited, especially the group of PCR
391 positive anti-NP negative subjects; this could be considered an intrinsic limitation of this research
392 field, since only 1-10% of PCR confirmed cases are estimated to have undetectable antibodies. In
393 addition, we acknowledge the fact that only four out of seven anti-NP negative, PCR positive
394 subjects in our cohort had given their consent for PBMC isolation from venous blood. The ex-vivo
395 assays were not performed using overlapping peptides covering the entire sequence of the SARS-
396 CoV-2 proteins, but only selected peptides were used; however, since they were found to be
397 immunogenic (17,27) we are confident that the results we obtained are representative, and are in
398 line with other studies reviewed by Bertoletti et al.(30).

399 We describe for the first time the β -NGF/TrkA signalling pathway as a host factor reflecting different
400 levels of inflammation within mild COVID-19 cases, with effects on the virus-specific humoral and T
401 cell response. The mechanistic regulation of this pathway in COVID-19 disease deserves further
402 investigation, and larger studies are required to determine whether the effects of such differences
403 can influence the durability of the T cell response and vaccine-induced immunity.

404 **Conflict of Interest**

405 This study was funded by Abbott Rapid Diagnostics as the sponsor. The authors declare that the
406 research was conducted independent of the sponsor. The authors have no further commercial or
407 financial relationships to disclose that could be construed as a potential conflict of interest.
408 Sponsor's Primary Contact: Camilla Forssten, Abbott Rapid Diagnostics, Clearblue Innovation
409 Centre, Priory Business Park, Bedford, MK44 3UP, UK, +44 7792 902 244, Fax +44 (0) 1234
410 759978, camilla.forssten@abbott.com.

411 **Author Contributions**

412 CU, USG and PTFK designed the research study; CU, JMG, CP and USG conducted the
413 experiments; CU, JMG, CP and USG acquired data; CU, WL and SRJ, AMK, USG analysed data;
414 AMK, USG and PTFK provided reagents; CU drafted the manuscript; all authors critically revised the
415 manuscript and approved the final version.

416

417 **Acknowledgments**

418 The authors would like to thank Dr Louisa James (Blizard Institute, Barts and The London SMD,
419 QMUL), Dr Sefina Arif and Norkhairin Yusuf (King's College London) for technical assistance. We
420 would also like to thank all clinical and administrative staff at The Graham Hayton Unit, Royal
421 London Hospital for aiding with recruitment and clinical sample collection.

422

References

- 424 1. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and
425 Treatment Coronavirus (COVID-19). StatPearls. StatPearls Publishing; 2020. Available from:
426 <http://www.ncbi.nlm.nih.gov/pubmed/32150360>
- 427 2. Choudhry N, Drysdale K, Usai C, Leighton D, Sonagara V, Buchanan R, et al. Disparities of
428 SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK. *Front*
429 *Med.* 2021 Apr 27;1:642723. Available from: <http://doi.org/10.3389/fmed.2021.642723>
- 430 3. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJAA, et al. Longitudinal
431 observation and decline of neutralizing antibody responses in the three months following
432 SARS-CoV-2 infection in humans. *Nat Microbiol.* 2020 Dec 26;5(12):1598–607. Available
433 from: <http://dx.doi.org/10.1038/s41564-020-00813-8>
- 434 4. Marklund E, Leach S, Axelsson H, Nyström K, Norder H, Bemark M, et al. Serum-IgG
435 responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-
436 responders. Walsh SR, editor. *PLoS One.* 2020 Oct 21;15(10):e0241104. Available from:
437 <https://dx.plos.org/10.1371/journal.pone.0241104>
- 438 5. Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early induction of
439 functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease
440 in COVID-19 patients. *Cell Rep.* 2021 Jan;34(6):108728. Available from:
441 <https://doi.org/10.1016/j.celrep.2021.108728>
- 442 6. Kutsuna S, Asai Y, Matsunaga A, Kinoshita N, Terada M, Miyazato Y, et al. Factors
443 associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from
444 COVID-19. *J Infect Chemother.* 2021 Jun 1;27(6):808–13. Available from:
445 <https://doi.org/10.1016/j.jiac.2021.01.006>
- 446 7. Pathak GA, Singh K, Miller-Fleming TW, Wendt FR, Ehsan N, Hou K, et al. Integrative
447 genomic analyses identify susceptibility genes underlying COVID-19 hospitalization. *Nat*
448 *Commun.* 2021 Dec;12(1). Available from: <https://doi.org/10.1016/j.jiac.2021.01.006>
- 449 8. Shelton JF, Shastri AJ, Ye C, Weldon CH, Filshtein-Sonmez T, Coker D, et al. Trans-ancestry
450 analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and
451 severity. *Nat Genet.* 2021 Jun 1;53(6):801–8. Available from: <https://doi.org/10.1038/s41588-021-00854-7>
- 452
- 453 9. Buszko M, Nita-Lazar A, Park JH, Schwartzberg PL, Verthelyi D, Young HA, et al. Lessons
454 learned: new insights on the role of cytokines in COVID-19. *Nat Immunol.* 2021 Mar
455 15;22(4):404–11. Available from: <https://doi.org/10.1038/s41590-021-00901-9>
- 456 10. Schlickeiser S, Schwarz T, Steiner S, Wittke K, Al Beshar N, Meyer O, et al. Disease
457 Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
458 *Front Immunol.* 2021 Jan 29;11. Available from: <https://doi.org/10.3389/fimmu.2020.628971>
- 459 11. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al.
460 Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med.* 2020 Oct
461 29;383(18):1724–34. Available from: <https://doi.org/10.1016/j.cell.2020.08.017>
- 462 12. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing
463 antibodies to SARS-CoV-2 infection persist for months. *Science (80-).* 2020 Dec
464 4;370(6521):1227–30. Available from: <https://doi.org/10.1016/j.cell.2020.08.017>

- 465 13. Sekine T, Perez-potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T
466 cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell*.
467 2020;183(1):158-168.e14. Available from: <http://doi.org/10.1016/j.cell.2020.08.017>
- 468 14. Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, et al. Discordant
469 neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.
470 *Sci Immunol*. 2020 Dec 23;5(54). Available from:
471 <https://doi.org/10.1126/SCIIMMUNOL.ABF3698>
- 472 15. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in SARS-CoV-
473 2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in
474 Population-Based Seroprevalence Studies. *J Virol*. 2020 Nov 3;95(3). Available from:
475 <https://doi.org/10.1128/jvi.01828-20>
- 476 16. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T
477 Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
478 Unexposed Individuals. *Cell*. 2020 Jun 25;181(7):1489-1501.e15. Available from:
479 <https://doi.org/10.1016/j.cell.2020.05.015>
- 480 17. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4+ and
481 CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. *Nat Immunol*.
482 2020;21(11):1336–45. Available from: <https://doi.org/10.1038/s41590-020-0782-6>
- 483 18. Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, et al.
484 COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral
485 responses. *Immunity*. 2021 Feb;54(2):340-354.e6. Available from:
486 <https://doi.org/10.1016/j.immuni.2021.01.008>
- 487 19. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific
488 T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature*.
489 2020;584(7821):457–62. Available from: <https://doi.org/10.1038/s41586-020-2550-z>
- 490 20. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct Early Serological
491 Signatures Track with SARS-CoV-2 Survival. *Immunity*. 2020 Sep 15;53(3):524-532.e4.
492 Available from: <https://doi.org/10.1016/j.immuni.2020.07.020>
- 493 21. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and
494 IgG responses in COVID-19 patients. *Emerg Microbes Infect*. 2020 Jan 1;9(1):940–8.
495 Available from: <https://doi.org/10.1080/22221751.2020.1762515>
- 496 22. Ehrhard PB, Erb P, Graumann U, Otten U. Expression of nerve growth factor and nerve
497 growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. *Proc Natl
498 Acad Sci U S A*. 1993 Dec 1;90(23):10984–8. Available from:
499 <https://doi.org/10.1073/pnas.90.23.10984>
- 500 23. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human
501 B lymphocytes. *Proc Natl Acad Sci U S A*. 1989 Dec 1;86(24):10059–63. Available from:
502 <https://doi.org/10.1073/pnas.86.24.10059>
- 503 24. Lambiase A, Bracci-Laudiero L, Bonini S, Bonini S, Starace G, D'Elia MM, et al. Human
504 CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve
505 growth factor receptors. *J Allergy Clin Immunol*. 1997;100(3):408–14. Available from:
506 [https://doi.org/10.1016/S0091-6749\(97\)70256-2](https://doi.org/10.1016/S0091-6749(97)70256-2)

- 507 25. Freund-Michel V, Frossard N. The nerve growth factor and its receptors in airway
508 inflammatory diseases. *Pharmacol Ther.* 2008;117(1):52–76. Available from:
509 <http://doi.org/10.1016/j.pharmthera.2007.07.003>
- 510 26. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-
511 2 infection rescues B and T cell responses to variants after first vaccine dose. *Science.* 2021
512 Apr 30;1282(April):1–11. Available from: <http://doi.org/10.1126/science.abh1282>
- 513 27. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology
514 and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-
515 CoV-2. *Cell Host Microbe.* 2020;1–10. Available from:
516 <https://doi.org/10.1016/j.chom.2020.03.002>
- 517 28. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus
518 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the
519 Chinese Center for Disease Control and Prevention. Vol. 323, *JAMA - Journal of the*
520 *American Medical Association.* American Medical Association; 2020. p. 1239–42. Available
521 from: <https://doi.org/10.1001/jama.2020.2648>
- 522 29. Steiner S, Schwarz T, Corman VM, Sotzny F, Bauer S, Drosten C, et al. Reactive T Cells in
523 Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. *Front*
524 *Immunol.* 2021 Jul 12;12. Available from: <https://doi.org/10.3389/fimmu.2021.687449>
- 525 30. Bertoletti A, Tan AT, Le Bert N. The T-cell response to SARS-CoV-2: kinetic and quantitative
526 aspects and the case for their protective role. *Oxford Open Immunol.* 2021 Jan 6;2(1):1–9.
527 Available from: <https://doi.org/10.1093/oxfimm/iqab006>
- 528 31. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, et al. Pre-existing
529 polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature.* 2021 Nov
530 10; Available from: <https://doi.org/10.1038/S41586-021-04186-8>
- 531 32. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on
532 the sensory and sympathetic nervous system of the chick embryo. *J Exp Zool.*
533 1951;116(2):321–61. Available from: <https://doi.org/10.1002/jez.1401160206>
- 534 33. Cohen S, Levi-Montalcini R, Hamburger V. A Nerve Growth-Stimulating Factor Isolated From
535 Sarcomas 37 And 180. *Proc Natl Acad Sci.* 1954 Oct 1;40(10):1014–8. Available from:
536 <https://doi.org/10.1073/pnas.40.10.1014>
- 537 34. Santambrogio L, Benedetti M, Chao M V, Muzaffar R, Kulig K, Gabellini N, et al. Nerve growth
538 factor production by lymphocytes. *J Immunol.* 1994;153(10):4488–95. Available from:
539 <http://www.jimmunol.org/content/153/10/4488>
- 540 35. Minnone G, De Benedetti F, Bracci-Laudiero L. NGF and its receptors in the regulation of
541 inflammatory response. Vol. 18, *International Journal of Molecular Sciences.* MDPI AG; 2017.
542 p. 1028. Available from: <http://doi.org/10.3390/ijms18051028>
- 543 36. Freund V, Pons F, Joly V, Mathieu E, Martinet N, Frossard N. Upregulation of nerve growth
544 factor expression by human airway smooth muscle cells in inflammatory conditions. *Eur*
545 *Respir J.* 2002 Aug 1;20(2):458–63. Available from:
546 <https://doi.org/10.1183/09031936.02.00269202>
- 547 37. Tsunoda S, Okumura T, Ito T, Mori Y, Soma T, Watanabe G, et al. Significance of nerve
548 growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma.

- 549 Br J Cancer. 2006 Aug 7;95(3):322–30. Available from: <https://doi.org/10.1038/sj.bjc.6603255>
- 550 38. Levanti MB, Germana A, Carlos F, Ciriaco E, Vega JA, Germana G. Effects of increased
551 nerve growth factor plasma levels on the expression of TrkA and p75NTR in rat testicles. J
552 Anat. 2006 Mar 1;208(3):373–9. Available from: [https://doi.org/10.1111/j.1469-
553 7580.2006.00528.x](https://doi.org/10.1111/j.1469-7580.2006.00528.x)
- 554 39. Othumpangat S, Gibson LF, Samsell L, Piedimonte G. NGF is an essential survival factor for
555 bronchial epithelial cells during respiratory syncytial virus infection. PLoS One. 2009;4(7).
556 Available from: <https://doi.org/10.1371/journal.pone.0006444>
- 557 40. Othumpangat S, Regier M, Piedimonte G. Nerve growth factor modulates human rhinovirus
558 infection in airway epithelial cells by controlling ICAM-1 expression. Am J Physiol - Lung Cell
559 Mol Physiol. 2012;302(10):1057–66. Available from:
560 <https://doi.org/10.1152/ajplung.00365.2011>
- 561

562 **Tables**563 **Table 1. SARS-CoV-2 peptide pools used for IFN- γ ELISpot assay and T cell expansion**
564 **experiments.**

Peptide ID (reference)	Protein	position	Sequence	Length	Pools ELISPOT	Pools T cell expansion
1 ^{A*}	S	973-987	ISSVLNDILSRDKV	15	S _a	S
2 ^{A*}	S	963-1007	IDRLITGRLQSLQTY	15		
3 ^{A*}	S	1217-1231	WLGFIAGLIAIVMVT	15		
4 ^B	S	166-180	CTFEYVSQPFLMDLE	15		
5 ^B	S	751-765	NLLLQYGSFCTQLNR	15	S _b	
6 ^B	S	801-815	NFSQILPDPSKPSKR	15		
7 ^B	S	866-880	TDEMIAQYTSALLAG	15		
8 ^{A*}	S	1011-1030	QLIRAAEIRASANLAATKMS	20		
9 ^{A*}	N	262-277	RTATKAYNVTQAFGRR	15	N	N
10 ^B	N	221-235	LLLLDRLNQLESKMS	15		
11 ^B	N	104-121	LSPRWYFYLLGTGPEAGL	18		
12 ^B	N	329-346	TWLYTGTGAIKLDDKDPNF	18		
13 ^B	N	352-369	LLNKHIDAYKTFPTEPK	18		
14 ^A	M	61-75	TLACFVLAAYRINW	15	M _a	M _a
15 ^B	M	133-150	LLESELVIGAVILRGHLR	18		
16 ^B	M	141-158	GAVILRGHLRIAGHHLGR	18		
17 ^B	M	149-166	LRIAGHHLGRCDIKDLPK	18	M _b	M _b
18 ^B	M	165-181	PKEITVATSRTLSTYYKL	17		
19 ^B	M	172-188	TSRTLSTYYKLGASQRVA	17		
20 ^B	ORF-7a-2a	9-25	LITLATCELYHYQECVR	17	ORF-7a-2a	ORF-7a-2a

565 * Indicates that the previously published peptides used were extended to reach a 15-amino acid
566 length. A) from Grifoni et al., 2020, Cell Host & Microbe; B) from; Peng Y. et al., 2020 Nature
567 Immunology

568

	N	Anti-NP IgG positive (N)	Anti-NP IgG Negative (N)
PCR positive	87	80	7
Symptomatic	71	67	4
Asymptomatic	16	13	3
PCR negative	23	3	20
Symptomatic	4	0	4
Asymptomatic	19	3	16
PCR N/A	118	20	98
Symptomatic	12	6	6
Asymptomatic	106	14	92
Total	228	103	125

569 **Table 2. Number of subjects shown from entire (2)**

570

571 **Table 3. Pearson correlation test between the Architect Index and serum cytokines levels**

Cytokine (pg/ml)	r	P value
GM-CSF	0.612	0.0007
β -NGF	0.5954	0.0011
IL-1 α	0.5164	0.0058
PBEF/Visfatin	0.4677	0.0139
IL-12 p70	0.3992	0.0391

572

573 **Table 4. Binary logistic regression between anti-NP IgG positivity and cytokines levels**

		Intercept	Standard Error	Wald chi-square test	Degrees of Freedom	P value	Odd ratio
Step 1 ^a	β -NGF (pg/ml)	2.401	0.929	6.679	1	0.010	11.038
	Constant	-6.594	2.430	7.364	1	0.007	0.001
a. Variable(s) entered on step 1: beta-NGF.							

574

575 **Figure Legends**

576 **Figure 1. Demonstration of SARS-CoV-2 specific IFN- γ ELISpot responses in relation to PCR**
577 **and anti-NP status.** PBMCs from convalescent COVID-19 subjects and unexposed volunteers were
578 incubated for 16 hours with peptide pools derived from four different SARS-CoV-2 proteins (M:
579 membrane; NP: nucleoprotein; ORF-7a-2: open reading frame 7a-2; S: spike). **(A)** The inner circle
580 represents the composition of the cohort according to PCR and anti-NP (antibody) status; the outer
581 circle represents the proportion of subjects producing IFN- γ (Responders) or absent of IFN- γ
582 production (Non-Responders), following incubation with the total SARS-CoV-2 peptide pool. **(B)** The
583 inner circle represents the number of samples in the cohort producing IFN- γ following incubation
584 with each of the peptide pools indicated; the outer circle represents the distribution of the IFN- γ -
585 producing samples across the four characterised groups according to PCR and antibody status.
586 N/A: not available.

587 **Figure 2. Discordant antibody (anti-NP and nAb) levels with IFN- γ ELISpot responses relative**
588 **to T cell antigens. (A)** Anti-nucleoprotein IgG levels expressed as Architect Index (manufacturer
589 arbitrary units) for each subject analysed (ordered lowest to highest level); the dotted line represents
590 the 1.4 cut-off, below which samples are considered as negatives. **(B)** Neutralising antibody (nAb)
591 titres (IC₅₀) corresponding to the same subjects in (A); the dotted line represents the cut-off below
592 which samples are considered as negatives (IC₅₀<50). **(C)** Cumulative T cell response to the four
593 peptide pools derived from SARS-CoV-2 expressed as spot-forming units (SFU) of IFN- γ -secreting
594 cells after 16-hour stimulation, ordered corresponding to the subjects in (A) and (B). (M: membrane;
595 NP: nucleoprotein; ORF-7a-2: open reading frame 7a-2; S: spike).


596 **Figure 3. Multi-specific CD4 and CD8 T cell intracellular cytokine responses subsequent to**
597 **peptide stimulation characterised according to PCR and antibody status.** Percentage of **(A)**
598 CD4⁺ and **(B)** CD8⁺ T cells respectively, producing IL-2, TNF- α , IFN- γ , and MIP-1 β after 16-hour
599 stimulation with selected peptide pools derived from SARS-CoV-2 (top); representative FACS plots
600 stimulated with the corresponding peptide pools (bottom). Ctrl: cells were incubated with RPMI as a
601 negative control. Percentage of subjects where **(C)** CD4⁺ and **(D)** CD8⁺ T cells produce the
602 cytokines IL-2, TNF- α , IFN- γ , and MIP-1 β after 16-hour stimulation with selected peptide pools
603 within each group. (M: membrane; NP: nucleoprotein; ORF-7a-2: open reading frame 7a-2; S:
604 spike). p- values determined by a two-way ANOVA with a Tukey's post-hoc test for multiple
605 comparisons. *p<0.05; **p<0.01; ***p<0.001, ****p<0.0001. (PCR-Ab- n=10; PCR+Ab+ N=10;
606 PCR+Ab- n=7).

607 **Figure 4. Differential T cells responses, pursuant to the number and type of cytokine**
608 **produced within the different cohorts. (A) CD4⁺ and (B) CD8⁺ T cells producing cytokines after**
609 **stimulation with the four peptide pools derived from SARs-CoV-2. The pie charts represent the**
610 **proportion of subjects producing a different number of cytokines per group in response to each of**
611 **the four peptide pools; the arcs show the production of each analysed cytokine, each corresponding**
612 **to a different colour as indicated. (M: membrane; NP: nucleoprotein; ORF-7a-2: open reading frame**
613 **7a-2; S: spike). (PCR-Ab- n=9; PCR+Ab+ n=8; PCR+Ab- n=4).**

614 **Figure 5. Distinct serum cytokine profiles in the subject cohorts and relative to antibody**
615 **status. (A) Heatmap showing differential serum cytokine expression in the study subjects listed**
616 **accordingly to respective anti-nucleoprotein IgG levels (Architect Index). (B) β -NGF and (C) IL-1 α**
617 **serum levels within the 3 different subject cohorts; boxes extend from the 25th to 75th percentiles,**
618 **the line indicates the median, and the whiskers extend from the smaller to the largest values.**
619 **Correlative expression of β -NGF with respect to (D) Architect index and (E) nAb levels, within the**
620 **whole cohort. p-values in (B) and (C) were determined by a one-way ANOVA with a Tukey's post-**
621 **hoc test for multiple comparisons. A Spearman non-parametric correlation test was undertaken to**
622 **test significance in (D) and (E). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns - not significant.**
623 **(PCR-Ab- n=10; PCR+Ab+ N=10; PCR+Ab- n=7).**


624 **Figure 6. Global and antigen specific T cell expression of the β -NGF receptor TrkA, from the**
625 **different cohorts. Correlative expression of β -NGF against MFI of TrkA⁺ (A) CD4⁺ and (B) CD8⁺ T**
626 **cells from all subjects studied. Summary data of percentage TrkA⁺ (C) CD4⁺ and (D) CD8⁺ T cells**
627 **(top), with representative FACS plots (bottom) from each cohort. Summary data of MFI expression**
628 **of TrkA on (E) CD4⁺ and (F) CD8⁺ T cells (top); with representative MFI histograms from each cohort**
629 **(bottom). MFI of TrkA⁺ (G) CD4⁺ and (H) CD8⁺ T cells producing the respective cytokines after 16-**
630 **hour stimulation with the four peptide pools derived from SARS-CoV-2. A Spearman non-parametric**
631 **correlation test was undertaken to test significance in (A) and (B), a one-ANOVA (C-F) and a two-**
632 **way ANOVA (G, H) with a Tukey's post-hoc test for multiple comparisons was used to demonstrate**
633 **significance. Coloured lines for significance indicate changes relative to the corresponding cytokine.**
634 ***p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns - not significant. (PCR-Ab- n=9; PCR+Ab+ n=8;**
635 **PCR+Ab- n=4).**

Figure 1



Responders
 Non- Responders

PCR- Ab-
 PCR+ Ab+
 PCR+ Ab-
 PCR N/A Ab+



Responders to M
 Responders to NP
 Responders to ORF-7a-2
 Responders to S

Figure 2






Figure 3





Figure 4




Figure 5




Figure 6

